174 related articles for article (PubMed ID: 19428125)
1. Lack of TIMP-1 increases severity of experimental autoimmune encephalomyelitis: Effects of darbepoetin alfa on TIMP-1 null and wild-type mice.
Thorne M; Moore CS; Robertson GS
J Neuroimmunol; 2009 Jun; 211(1-2):92-100. PubMed ID: 19428125
[TBL] [Abstract][Full Text] [Related]
2. Persistent macrophage/microglial activation and myelin disruption after experimental autoimmune encephalomyelitis in tissue inhibitor of metalloproteinase-1-deficient mice.
Crocker SJ; Whitmire JK; Frausto RF; Chertboonmuang P; Soloway PD; Whitton JL; Campbell IL
Am J Pathol; 2006 Dec; 169(6):2104-16. PubMed ID: 17148673
[TBL] [Abstract][Full Text] [Related]
3. Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking.
Göbel K; Pankratz S; Schneider-Hohendorf T; Bittner S; Schuhmann MK; Langer HF; Stoll G; Wiendl H; Kleinschnitz C; Meuth SG
J Autoimmun; 2011 Mar; 36(2):106-14. PubMed ID: 21216565
[TBL] [Abstract][Full Text] [Related]
4. Increased X-linked inhibitor of apoptosis protein (XIAP) expression exacerbates experimental autoimmune encephalomyelitis (EAE).
Moore CS; Hebb AL; Blanchard MM; Crocker CE; Liston P; Korneluk RG; Robertson GS
J Neuroimmunol; 2008 Oct; 203(1):79-93. PubMed ID: 18687476
[TBL] [Abstract][Full Text] [Related]
5. Effect of natalizumab treatment on metalloproteinases and their inhibitors in a mouse model of multiple sclerosis.
Pyka-Fosciak G; Lis GJ; Litwin JA
J Physiol Pharmacol; 2020 Apr; 71(2):. PubMed ID: 32776909
[TBL] [Abstract][Full Text] [Related]
6. Treatment of experimental autoimmune encephalomyelitis with a neurotropic alphavirus vector expressing tissue inhibitor of metalloproteinase-2.
Nygårdas PT; Grönberg SA; Heikkilä J; Joronen K; Sorsa T; Hinkkanen AE
Scand J Immunol; 2004 Oct; 60(4):372-81. PubMed ID: 15379862
[TBL] [Abstract][Full Text] [Related]
7. Bax-ablation attenuates experimental autoimmune encephalomyelitis in mice.
Lev N; Barhum Y; Melamed E; Offen D
Neurosci Lett; 2004 Apr; 359(3):139-42. PubMed ID: 15050683
[TBL] [Abstract][Full Text] [Related]
8. The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE).
Musgrave T; Benson C; Wong G; Browne I; Tenorio G; Rauw G; Baker GB; Kerr BJ
Brain Behav Immun; 2011 Nov; 25(8):1677-88. PubMed ID: 21723939
[TBL] [Abstract][Full Text] [Related]
9. VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE.
Roscoe WA; Welsh ME; Carter DE; Karlik SJ
J Neuroimmunol; 2009 Apr; 209(1-2):6-15. PubMed ID: 19233483
[TBL] [Abstract][Full Text] [Related]
10. Opioid growth factor arrests the progression of clinical disease and spinal cord pathology in established experimental autoimmune encephalomyelitis.
Campbell AM; Zagon IS; McLaughlin PJ
Brain Res; 2012 Sep; 1472():138-48. PubMed ID: 22820301
[TBL] [Abstract][Full Text] [Related]
11. Glutathione PEGylated liposomal methylprednisolone (2B3-201) attenuates CNS inflammation and degeneration in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis.
Lee DH; Rötger C; Appeldoorn CC; Reijerkerk A; Gladdines W; Gaillard PJ; Linker RA
J Neuroimmunol; 2014 Sep; 274(1-2):96-101. PubMed ID: 25037177
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of reactive astrocytosis in established experimental autoimmune encephalomyelitis favors infiltration by myeloid cells over T cells and enhances severity of disease.
Toft-Hansen H; Füchtbauer L; Owens T
Glia; 2011 Jan; 59(1):166-76. PubMed ID: 21046558
[TBL] [Abstract][Full Text] [Related]
13. Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis.
Noorbakhsh F; Tsutsui S; Vergnolle N; Boven LA; Shariat N; Vodjgani M; Warren KG; Andrade-Gordon P; Hollenberg MD; Power C
J Exp Med; 2006 Feb; 203(2):425-35. PubMed ID: 16476770
[TBL] [Abstract][Full Text] [Related]
14. Pathological findings in rats with experimental allergic encephalomyelitis.
Dong M; Liu R; Guo L; Li C; Tan G
APMIS; 2008 Nov; 116(11):972-84. PubMed ID: 19132994
[TBL] [Abstract][Full Text] [Related]
15. Experimental allergic encephalomyelitis. T cell trafficking to the central nervous system in a resistant Thy-1 congenic mouse strain.
Skundric DS; Huston K; Shaw M; Tse HY; Raine CS
Lab Invest; 1994 Nov; 71(5):671-9. PubMed ID: 7526038
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis.
Feinstein DL; Galea E; Gavrilyuk V; Brosnan CF; Whitacre CC; Dumitrescu-Ozimek L; Landreth GE; Pershadsingh HA; Weinberg G; Heneka MT
Ann Neurol; 2002 Jun; 51(6):694-702. PubMed ID: 12112074
[TBL] [Abstract][Full Text] [Related]
17. Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice.
Berard JL; Wolak K; Fournier S; David S
Glia; 2010 Mar; 58(4):434-45. PubMed ID: 19780195
[TBL] [Abstract][Full Text] [Related]
18. Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss.
Butzkueven H; Emery B; Cipriani T; Marriott MP; Kilpatrick TJ
Glia; 2006 May; 53(7):696-703. PubMed ID: 16498619
[TBL] [Abstract][Full Text] [Related]
19. Anti-inflammatory effect of erythropoietin therapy on experimental autoimmune encephalomyelitis.
Zhang X; Li QY; Xiao BG
Int J Neurosci; 2012 May; 122(5):255-62. PubMed ID: 22176555
[TBL] [Abstract][Full Text] [Related]
20. Focal experimental autoimmune encephalomyelitis in the Lewis rat induced by immunization with myelin oligodendrocyte glycoprotein and intraspinal injection of vascular endothelial growth factor.
Sasaki M; Lankford KL; Brown RJ; Ruddle NH; Kocsis JD
Glia; 2010 Oct; 58(13):1523-31. PubMed ID: 20645414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
